Bile duct cancer, known medically as cholangiocarcinoma, is a rare cancer that forms in the thin tubes (bile ducts) that carry digestive fluid from your liver to your small intestine. It is the second most common primary liver cancer, and it tends to be difficult to detect early because symptoms often don’t appear until the disease has progressed. The five-year survival rate ranges from about 37% when caught early and still confined to one site, down to roughly 3.6% once the cancer has spread to distant organs.
Where Bile Duct Cancer Forms
Your bile ducts form a branching network inside and outside the liver. Cancer can develop anywhere along this network, and its exact location determines the type, the symptoms you experience, and how doctors approach treatment. There are three recognized types:
- Intrahepatic: Forms inside the liver, in the smaller bile duct branches embedded in liver tissue.
- Perihilar (Klatskin tumor): Develops where the right and left hepatic ducts merge and exit the liver. This is the most common location.
- Distal: Occurs in the common bile duct, the portion closest to the small intestine and pancreas.
These distinctions matter because each type behaves differently. Intrahepatic tumors often grow as a mass within the liver and may be mistaken for other liver cancers on imaging. Perihilar and distal tumors tend to cause noticeable blockages in bile flow earlier, which can lead to symptoms that prompt medical attention sooner.
Symptoms and Warning Signs
The hallmark symptom is jaundice, a yellowing of the skin and the whites of the eyes. This happens when a tumor blocks a bile duct and bile pigment backs up into the bloodstream. Jaundice from bile duct cancer is typically painless at first, which distinguishes it from jaundice caused by gallstones (which usually comes with sudden, sharp pain).
Other common signs include:
- White or clay-colored stools: Bile gives stool its brown color. When bile can’t reach the intestine, stools turn pale.
- Dark urine: Excess bile pigment is filtered by the kidneys instead, darkening the urine.
- Intense itching: Bile salts depositing in the skin cause persistent, sometimes severe itchiness.
- Right-sided abdominal pain: A dull ache just below the ribs on the right side.
- Unexplained weight loss, fatigue, fever, and night sweats.
Intrahepatic bile duct cancer is the most likely type to be “silent” in its early stages, since tumors deep inside the liver can grow without blocking bile flow. By contrast, perihilar and distal tumors often cause jaundice earlier simply because they sit in narrower ducts where even a small growth creates a blockage.
How It Is Diagnosed
Diagnosis usually starts with blood work. Liver function tests can reveal elevated levels that suggest bile isn’t draining properly. Doctors also check for a protein called CA 19-9, which bile duct cancer cells tend to overproduce. An elevated CA 19-9 level isn’t proof of cancer on its own, but it adds another piece to the puzzle.
Imaging comes next. Ultrasound is often the first step, followed by CT scans or MRI. A specialized MRI technique called MRCP (magnetic resonance cholangiopancreatography) can create detailed 3D images of the bile ducts without requiring any dye injection or invasive procedure, and it’s increasingly used as a first-line imaging tool.
If more detail is needed, doctors may perform an ERCP. In this procedure, a thin, flexible tube with a camera is passed through the mouth, down through the stomach, and into the small intestine where the bile ducts connect. Dye is injected into the ducts to make them visible on X-ray. During ERCP, doctors can also collect a tissue sample for biopsy. For tumors located inside the liver, a biopsy is more commonly done by guiding a fine needle through the skin using CT or ultrasound for precision.
Staging and What It Means
Bile duct cancer is staged from 0 to IV using the TNM system, with separate staging criteria for each of the three tumor locations. In general terms, Stage I means the cancer is small and confined to the bile duct wall. Stage II indicates the tumor has pushed through the duct wall into nearby tissue. Stage III means involvement of nearby blood vessels, organs, or lymph nodes. Stage IV indicates the cancer has spread to distant parts of the body such as the lungs, bones, or lining of the abdomen.
For intrahepatic tumors specifically, Stage IA describes a tumor 5 centimeters or smaller, while Stage IB is anything larger. By Stage II, the tumor has invaded a blood vessel or formed multiple growths. Stage IIIA means it has broken through the liver’s outer capsule.
Perhaps the most important distinction in staging is whether the cancer is resectable, meaning it can be completely removed with surgery. Most people with bile duct cancer are diagnosed at a point where complete surgical removal is not possible.
Survival Rates by Stage
Five-year relative survival data from the National Cancer Institute’s SEER database (covering 2016 to 2022) for liver and intrahepatic bile duct cancer shows a stark difference based on how far the cancer has spread at the time of diagnosis:
- Localized (confined to the original site): 37.4%
- Regional (spread to nearby lymph nodes): 13.4%
- Distant (metastasized to other organs): 3.6%
These numbers combine liver cancer and intrahepatic bile duct cancer, so they’re an approximation. They also reflect averages across many patients and don’t predict any individual outcome. Still, they illustrate why early detection makes such a dramatic difference.
Surgical Treatment
Surgery offers the best chance of a cure when the cancer is caught early enough. The type of operation depends on where the tumor sits.
For intrahepatic tumors, a partial hepatectomy removes the section of liver containing the cancer along with a margin of healthy tissue. The liver is unusual among organs in its ability to regenerate, so removing a portion or even an entire lobe is sometimes feasible.
For distal tumors near the pancreas, a Whipple procedure (pancreatoduodenectomy) is the standard approach. This is a major operation that removes part of the pancreas, the duodenum, the gallbladder, and the affected section of the bile duct, then reconstructs the digestive tract. Recovery typically takes several weeks, and it requires significant surgical expertise.
Perihilar tumors are among the most surgically challenging because of their proximity to critical blood vessels entering the liver. In select cases, liver transplantation has been used for perihilar bile duct cancer, though strict criteria must be met.
When Surgery Isn’t an Option
For the majority of patients whose cancer cannot be fully removed, treatment focuses on controlling the disease and relieving symptoms. Chemotherapy, radiation, or a combination of both can slow tumor growth.
One of the most important palliative interventions is biliary stenting, placing a small tube inside the blocked bile duct to restore bile flow. This directly relieves jaundice, itching, and digestive problems. Stents are placed during an ERCP or through the skin and liver. Metal stents stay open longer than plastic ones, with one large study reporting a 98% success rate for placement and an average of about 288 days before blockage recurred. Plastic stents are cheaper but more prone to shifting out of position and clogging sooner. The stent doesn’t affect survival, but it can significantly improve quality of life.
Targeted Therapy for Specific Mutations
A meaningful development in bile duct cancer treatment has been the arrival of drugs that target specific genetic changes found in some tumors. Not all bile duct cancers carry these mutations, so tumor tissue is typically tested after diagnosis to check.
One important target is a genetic rearrangement in a growth-signaling gene called FGFR2, found in a subset of intrahepatic bile duct cancers. The FDA has approved drugs for patients whose tumors carry this specific change. In clinical trials, about 42% of patients with this mutation saw their tumors shrink with treatment, and responses lasted a median of nearly 10 months. Drugs targeting a different mutation, in a gene involved in cell metabolism called IDH1, have also been approved for certain patients.
These therapies aren’t a fit for everyone, since only a fraction of bile duct cancers carry the relevant mutations. But for those who do, they represent a treatment option that didn’t exist a few years ago. Genetic testing of the tumor has become a routine part of the workup for advanced bile duct cancer for this reason.